Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The goal of this clinical research study is to measure the amount of inflammatory proteins inside the body before and after lymphatico-venular bypass surgery. This will help doctors learn if anti-fibrotic or anti-inflammatory drugs/treatments given with the surgery can improve how well the surgery works.
| Condition | Intervention |
|---|---|
|
Breast Cancer Genitourinary Cancer Malignant Female Reproductive System Neoplasm Melanoma Sarcoma |
Procedure: Punch Biopsy |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Determination of the Effect of Lymphatico-venous Bypass Surgery on Inflammatory Responses and Tissue Fibrosis |
- Th2 Cytokine Levels [ Time Frame: 6 months ] [ Designated as safety issue: No ]5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
| Estimated Enrollment: | 22 |
| Study Start Date: | March 2012 |
| Estimated Primary Completion Date: | March 2015 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
| Punch Biopsy |
Procedure: Punch Biopsy
5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
|
Detailed Description:
If you choose to take part in this study, you will have 1 small piece of tissue (about the size of a pencil eraser) collected from the arm with the lymphedema and another small piece of tissue will be collected from the unaffected arm. A total of 4 samples will be collected by excisional biopsy (2 samples before the surgery and 2 more samples again 6 months after the surgery). To collect an excisional biopsy, the area of skin is numbed with anesthetic and a small cut is made to remove all or part of the affected tissue.
Blood (about 5 teaspoons each time) will also be drawn before the surgery and 1 more blood sample again 6 months after the surgery. If possible, the blood samples will be collected during already scheduled blood draws to avoid additional needle sticks.
The tissue and blood samples will be used for testing to evaluate the level of the tissue inflammation and to check for any build-up of excess tissue.
Length of Study:
After both tissue and blood samples have been collected, your participation in this study will be over.
This is an investigational study.
Up to 30 patients will take part in this study. All will be enrolled at MD Anderson.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
UT MD Anderson Cancer Center patients, 18 years of age or older, undergoing lymphatico-venular bypass for stage II or greater lymphedema.
Inclusion Criteria:
- Patients undergoing lymphatico-venular bypass for lymphedema.
- History of axillary lymph node dissection, sentinel lymph node biopsy or dissection.
- A minimum of three (3) months post-op from any surgical interventions.
- A minimum of six (6) months from the last dose of chemotherapy.
- Patients with unilateral lymphedema.
Exclusion Criteria:
- Active systemic infection or allergic reaction.
- Active parasitic infection.
- History of primary (congenital) lymphedema.
- Metastatic cancer.
- History of autoimmune disorders including lupus, rheumatoid arthritis, vasculitis, systemic sclerosis.
- History of other fibroproliferative disorders including cirrhosis, pulmonary fibrosis, kidney fibrosis, systemic sclerosis, scleroderma.
- Current treatment with steroids.
- Concurrent secondary systemic cancer exclusive of cutaneous malignancies.
- Treatment with myelosuppressive or stimulatory drugs within six (6) months of enrollment.
- History of bone marrow transplantation.
Contacts and Locations| Contact: David W. Chang, MD | 713-794-1247 |
| United States, Texas | |
| UT MD Anderson Cancer Center | Recruiting |
| Houston, Texas, United States, 77030 | |
| Principal Investigator: | David W. Chang, MD | UT MD Anderson Cancer Center |
More Information
Additional Information:
No publications provided
| Responsible Party: | M.D. Anderson Cancer Center |
| ClinicalTrials.gov Identifier: | NCT01433302 History of Changes |
| Other Study ID Numbers: | 2011-0455 |
| Study First Received: | September 8, 2011 |
| Last Updated: | May 29, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by M.D. Anderson Cancer Center:
|
Breast cancer Genitourinary cancer Gynecological cancer Malignant Female Reproductive System Neoplasm Melanoma Sarcoma Inflammatory Response |
Inflammatory proteins Tissue Fibrosis Lymphatico-venous Bypass Surgery Punch biopsy Lab collections Th2 immune phenotype Lymphedema |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms Fibrosis Genital Neoplasms, Female Melanoma Urogenital Neoplasms Sarcoma Neoplasms by Site Breast Diseases |
Skin Diseases Pathologic Processes Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Nerve Tissue Nevi and Melanomas Neoplasms, Connective and Soft Tissue |
ClinicalTrials.gov processed this record on June 17, 2013